• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Human Normal Immunoglobulin
    9 Drugs classified under this active ingredient


    All the Active Ingredient Drugs

    Filter by letter: ALL A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
    Beriglobin P
    Genmedix
    RX
    partial basket chart
    Beriglobin P

    Immunoglobulins. Human Normal Immunoglobulin 160 mg/ml.
    PFS: 1 x 2 cc, 5 cc. See lit.
    Defic. defect. antibody synth., protracted
    transitory hypogammaglobulem.,
    proph. hepatit. A, measles or attenuat.
    measles.
    C/I: Severe thrombocytopen., other
    coag. disords., isolated immunoglobulin
    A (IgA) defic.

    Flebogamma 5% DIF
    Medici
    RX
    partial basket chart
    Flebogamma 5% DIF

    Human Normal Immunoglobulin 0.5 g / 10 ml.
    VIALS: 1 x 0.5 g, 2.5 g, 5 g, 10 g. See lit.
    Replacement ther. in: Prim. immunodefic.
    synds. such as: congen.
    agammaglobulinem./
    hypogammaglobulinem; common
    variable immunodefic.; severe combined
    immunodefic.; Wiscott Aldrich syndr.
    Myeloma/chron. lympocyt. leukem. with
    severe second. hypogammaglobuline.
    and recurr. infects. Child with congenital
    AIDS and recurr. infects.
    Immunomodulat: ITP in child or adults at
    high risk of bleed./prior to surgery to
    correct the platelet count. Guillain Barre
    syndr., Kawasaki dis., allogeneic bone
    marrow transplant.
    C/I: History anaphylact. or severe
    system. response to I.M./I.V.
    immunoglob. preps.

    Gamunex C
    Perrigo
    RX
    partial basket chart
    Gamunex C

    Human Normal Immunoglobulin 0.1 gr/ml.
    VIAL: 1 x 10 ml, 25 ml, 50 ml, 100 ml.
    See lit.
    Prim. immunodefic. (PI), idiopath.
    thrombocytopen. purpura (ITP). Chron.
    inflamm. demyelinat. polyneuropath.
    (CIDP).
    C/I: Known anaphylact./severe system.
    response to human immunoglob.,
    severe select. IgA defic. See lit.

    Intratect 100 g/l
    Kamada
    RX
    partial basket chart
    Intratect 100 g/l

    Immunoglobulins. Human Normal Immunoglobulin 100 g/l.
    VIAL (sol.for infus.): 10, 25, 50, 100, 200 ml.
    Replacem. ther. in primary immunodefic., init. dose: 0.4-0.8 g/kg, thereafter 0.2-0.8 g/kg every 3-4 wks. to obtain IgG trough level of IgG of at least 6 g/l. Replacem. ther. in second. immunodefic.: 0.2-0.4 g/kg, every 3-4 wks. Prim. immune thrombocytop.: 0.8-1 g/kg on day 1, possibly rpt once within 3 days, or 0.4 g/kg/d for 2-5 d. Guillain Barré syndr.: 0.4 g/kg/d for 5 d (possible rpt of dosing in case of relapse). Kawasaki dis.: 2 g/kg should be admin. as a sgle. dose. Pts should receive concom. tmt with acetylsalicylic acid. CIDP Starting dose: 2 g/kg div. over 2 -5 consecutive d. Mainten. doses: 1 g/kg over 1-2 consecutive d every 3 wks. MMN starting dose: 2 g/kg given over 2-5 consecut. days. Mainten. dose: 1 g/kg every 2 to 4 wks or 2 g/kg every 4 to 8 wks.
    Replacem. ther. in adults, child. and adolesc. (0-18 years) in: Primary immunodefic. syndr. (PID) with impair. antibod. prod. Second. Immunodefic. (SID) in pts with sev. or recur. infect., ineffective antimicrob. tmt and either PSAF or serum IgG level of <4 g/l. Immunomodul. in adults, child. and adolesc. (0-18 years) in:Primary ITP, in pts at high risk of bleed. or prior to surg. to correct platelet count. Guillain Barré syndr. Kawasaki dis. (in conjunct. w/acetylsalicylic acid). Chronic inflamm. demyelin. polyradiculoneuropathy (CIDP). Multifocal motor neuropathy (MMN).
    C/I: Hypersens. to the active subst. or to any of the excip. Pts. with selective IgA defic. who develop antibod. to IgA, as admin. of IgA-contain. product can result in anaphylax.

    Intratect 50 g/l
    Kamada
    RX
    partial basket chart
    Intratect 50 g/l

    Immunoglobulins. Human Normal Immunoglobulin 50 mg/ml.
    VIAL (sol.for infus.): 20, 50, 100, 200 ml.
    Replacem. ther. in primary immunodefic., init. dose: 0.4-0.8 g/kg, thereafter 0.2-0.8 g/kg every 3-4 wks. to obtain IgG trough level of IgG of at least 6 g/l. Replacem. ther. in second. immunodefic.: 0.2-0.4 g/kg, every 3-4 wks. Prim. immune thrombocytop.: 0.8-1 g/kg on day 1, possibly rpt once within 3 days, or 0.4 g/kg/d for 2-5 d. Guillain Barré syndr.: 0.4 g/kg/d for 5 d (possible rpt of dosing in case of relapse). Kawasaki dis.: 2 g/kg should be admin. as a sgle. dose. Pts should receive concom. tmt with acetylsalicylic acid. CIDP Starting dose: 2 g/kg div. over 2 -5 consecutive d. Mainten. doses: 1 g/kg over 1-2 consecutive d every 3 wks. MMN starting dose: 2 g/kg given over 2-5 consecut. days. Mainten. dose: 1 g/kg every 2 to 4 wks or 2 g/kg every 4 to 8 wks.
    Replacem. ther. in adults, child. and adolesc. (0-18 years) in: Primary immunodefic. syndr. (PID) with impair. antibod. prod. Second. Immunodefic. (SID) in pts with sev. or recur. infect., ineffective antimicrob. tmt and either PSAF or serum IgG level of <4 g/l. Immunomodul. in adults, child. and adolesc. (0-18 years) in:Primary ITP, in pts at high risk of bleed. or prior to surg. to correct platelet count. Guillain Barré syndr. Kawasaki dis. (in conjunct. w/acetylsalicylic acid). Chronic inflamm. demyelin. polyradiculoneuropathy (CIDP). Multifocal motor neuropathy (MMN).
    C/I: Hypersens. to the active subst. or to any of the excip. Pts. with selective IgA defic. who develop antibod. to IgA, as admin. of IgA-contain. product can result in anaphylax.

    Kiovig
    Takeda
    RX
    partial basket chart
    Kiovig

    Human Normal Immunoglobulin 100 mg/ml.
    VIAL (sol. for infus.): 1 x 10, 25, 50, 100,
    200, 300 ml. See lit.
    Replace. ther. in : Prim. immunodefic
    syndrs. with impaired antibody product.,
    hypogammaglobulinem., recurr. bact.
    infects. with chron. lymphoc. leukem. in
    whom prophylact. antibiotics failed,
    hypogammaglobulinem. and recurr.
    bact. infects in plateau phase multiple
    myeloma with failed response to
    pneumococc. imunizat., child and
    adolesc. (0-18 yrs) with congen. AIDS and
    recurr. bact. infects.,
    hypogammaglobulinem. aft. allogen.
    hematopoiet. stem cell transplant.
    (HSCT). Immunomodulat: Primary
    immune thrombocytopenia (ITP), in high
    risk of bleed/prior to surg. to correct
    platelet count. Guillain Barre syndr.,
    Kawasaki dis.
    C/I:
    Hypersens. to product., to human
    immunoglobulins. See lit.

    CLOSE